Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology ...

A Lagos resident, Alfred Ogene, has filed a formal legal claim against R-Jolad Hospital Nigeria Limited, alleging gross medical negligence.According to the claim, the alleged negligence resulted in ...

For generations, men have been taught that standing to pee is natural, efficient, and even a badge of masculinity. Bathrooms ...

If you're regularly woken up at night needing to use the toilet, it could indicate an underlying health condition ...

Waking up in the night to use the toilet is often harmless, but frequent trips could indicate an underlying condition ...

This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic ...

Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a ...

Bladder stones (vesical calculi) almost always form due to an underlying issue like urinary stasis, obstruction, or foreign bodies. High-risk populations include women with pelvic organ prolapse and ...

Hyponatraemia is a frequent complication after joint replacement surgeries, often arising from fluid and electrolyte imbalances in the postoperative period. In a new article published in BMC ...

Independent 2025 Review Examines How NewEra Protect Combines Kidney Support, Bladder Strength, and Pelvic Floor Recovery. Backed by Clinical-Grade Ingredients and a Verified 60-Day Refund Guarantee.

See disclosure here or remove ads. NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel designed to enable bladder retention and gradual drug release over 10 days.

FDA feedback supports 2 potential registrational trials - 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled trial in intermediate-risk NMIBC. FDA ...